Andrew J. Cutler graduated from Haverford College in Pennsylvania and received his MD degree from the University of Virginia School of Medicine in 1989. He completed Internship and Residencies in both Psychiatry and Internal Medicine at the University of Virginia Medical Center and served as Chief Resident in the Department of Psychiatric Medicine. He has been Board Certified in both Psychiatry and Internal Medicine and has been conducting clinical research since 1993 at the University of Virginia, the University of Chicago, and since 1996, in Central Florida. Dr. Cutler also speaks to professional and community audiences about the evaluation and treatment of mental illnesses such as ADHD, Bipolar Disorder (Manic-Depression), Major Depression, Anxiety Disorders and Schizophrenia.
He conducts clinical trials for Phase I-IV studies. Indications include ADHD in children, adolescents and adults, depression, anxiety, bipolar disorder, schizophrenia and other neuropsychiatric and medical conditions.
In addition to being the Chief Medical Officer for Meridien Research, Dr. Cutler is a Courtesy Assistant Professor of Psychiatry at the University of Florida. Dr. Cutler regularly authors scientific publications in respected medical journals and presents his research at scientific meetings around the world. He serves on scientific and pharmaceutical Editorial and Advisory Boards and performs peer reviews of articles to help with their publication. He teaches and lectures doctors and other health care professionals and is in great demand as a public speaker. Dr. Cutler received the “Distinguished Clinical Professional Award” by the Central Florida chapter of the National Mental Health Association in 1999. He was also selected as a Top Doctor by Orlando magazine in 2002, 2003, 2004, 2005, 2006 and 2007.
Papers and Posters
Dr. Andrew Cutler conducts clinical trials for Phase I-IV studies. Indications include ADHD in children, adolescents and adults, depression, anxiety, bipolar disorder, schizophrenia and other neuropsychiatric and medical conditions. Read below for some of his most recent contributions.
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting
Alzheimer’s Disease & Dementia
Pseudobulbar Affect (PBA)